Ironwood Pharmaceuticals (NASDAQ: IRWD) reports proposed RSU sales via Form 144

Rhea-AI Filing Summary

Ironwood Pharmaceuticals reported proposed sales of Class A common stock via a Form 144 tied to restricted stock unit awards, including awards of 62,218 (03/08/2022), 80,198 (03/08/2023), 88,292 (03/05/2024) and 180,000 (05/20/2025) shares.

Each listed award was granted under the Issuer's 2019 Equity Incentive Plan or its amended and restated 2019 Equity Incentive Plan. The filing lists the securities and grant dates associated with the proposed sales.

Insights

Securities Compliance Counsel

Form 144 reports proposed resale of RSU-derived Class A shares with specific grant dates and counts.

The filing identifies restricted stock unit awards granted under the 2019 Equity Incentive Plan and its amended and restated form, listing discrete award amounts tied to 03/08/2022, 03/08/2023, 03/05/2024, and 05/20/2025. This notifies the market of intended Rule 144 sales procedures.

Actual sale timing, methods, and proceeds treatment are determined by holder actions and applicable Rule 144 conditions; subsequent filings may disclose transaction completion details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Common Stock	E Trade Securities LLC 3 Edison Drive Alpharetta GA 30005	182185	839872.85	162678647	02/23/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Common Stock	03/08/2022	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			62218	03/08/2022	N/A
Class A Common Stock	03/08/2023	Restricted Stock Unit award granted pursuant to the Issuer's 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			80198	03/08/2023	N/A
Class A Common Stock	03/05/2024	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			88292	03/05/2024	N/A
Class A Common Stock	05/20/2025	Restricted Stock Unit award granted pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan, subject to vesting requirements	Ironwood Pharmaceuticals, Inc.			180000	05/20/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ironwood's (IRWD) Form 144 disclose?

It discloses proposed sales of Class A common stock tied to RSU awards. The filing lists awards of 62,218, 80,198, 88,292, and 180,000 shares with grant dates in 2022–2025 under the company's equity plans.

Which equity plan granted the shares referenced in IRWD's Form 144?

The awards were granted under the company's 2019 Equity Incentive Plan and its amended and restated 2019 Equity Incentive Plan. The filing ties each listed award amount to the specific grant date shown in the record.

Do the Form 144 entries show total shares to be sold for IRWD?

The filing lists individual restricted stock unit award amounts and grant dates rather than a single aggregate offering total. It identifies awards of 62,218, 80,198, 88,292, and 180,000 shares tied to specific grant dates.

Who is the issuer and trading venue shown on the Form 144 for IRWD?

The issuer is Ironwood Pharmaceuticals, Inc., and the securities are Class A common stock listed on Nasdaq. The filing identifies the broker/dealer contact as E Trade Securities LLC in Alpharetta, GA.